A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains
- PMID: 22022282
- PMCID: PMC3192835
- DOI: 10.1371/journal.pgen.1002322
A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains
Abstract
Despite evidence of the clustering of metabolic syndrome components, current approaches for identifying unifying genetic mechanisms typically evaluate clinical categories that do not provide adequate etiological information. Here, we used data from 19,486 European American and 6,287 African American Candidate Gene Association Resource Consortium participants to identify loci associated with the clustering of metabolic phenotypes. Six phenotype domains (atherogenic dyslipidemia, vascular dysfunction, vascular inflammation, pro-thrombotic state, central obesity, and elevated plasma glucose) encompassing 19 quantitative traits were examined. Principal components analysis was used to reduce the dimension of each domain such that >55% of the trait variance was represented within each domain. We then applied a statistically efficient and computational feasible multivariate approach that related eight principal components from the six domains to 250,000 imputed SNPs using an additive genetic model and including demographic covariates. In European Americans, we identified 606 genome-wide significant SNPs representing 19 loci. Many of these loci were associated with only one trait domain, were consistent with results in African Americans, and overlapped with published findings, for instance central obesity and FTO. However, our approach, which is applicable to any set of interval scale traits that is heritable and exhibits evidence of phenotypic clustering, identified three new loci in or near APOC1, BRAP, and PLCG1, which were associated with multiple phenotype domains. These pleiotropic loci may help characterize metabolic dysregulation and identify targets for intervention.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689. - PubMed
-
- Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295–309. - PubMed
-
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480. - PubMed
-
- Treatment PanelATP., III Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. - PubMed
-
- Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–443. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK078616/DK/NIDDK NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- N01 HC045205/HL/NHLBI NIH HHS/United States
- N01 HC055020/HL/NHLBI NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- N01 HC085084/HC/NHLBI NIH HHS/United States
- K99-HL-098458/HL/NHLBI NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
- N01 HC045204/HL/NHLBI NIH HHS/United States
- N01 HC095095/HL/NHLBI NIH HHS/United States
- N01 HC085080/HL/NHLBI NIH HHS/United States
- N01 HC055016/HL/NHLBI NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- N01 HC095168/HL/NHLBI NIH HHS/United States
- U01CA98758/CA/NCI NIH HHS/United States
- N01 HC048048/HL/NHLBI NIH HHS/United States
- N01 HC055019/HL/NHLBI NIH HHS/United States
- U01 HG004790/HG/NHGRI NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- U01 HG004802/HG/NHGRI NIH HHS/United States
- U01 HG007416/HG/NHGRI NIH HHS/United States
- N01 HC055021/HL/NHLBI NIH HHS/United States
- N01 HC015103/HC/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- K99 HL098458/HL/NHLBI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- N01 HC048049/HL/NHLBI NIH HHS/United States
- N01 HC085085/HC/NHLBI NIH HHS/United States
- U01CA136792/CA/NCI NIH HHS/United States
- N01 HC055015/HL/NHLBI NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- N01 HC055222/HL/NHLBI NIH HHS/United States
- U01 HG004803/HG/NHGRI NIH HHS/United States
- P01 CA033619/CA/NCI NIH HHS/United States
- K24 DK080140/DK/NIDDK NIH HHS/United States
- N01 HC045134/HC/NHLBI NIH HHS/United States
- N01 HC005187/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- N01 HC048047/HL/NHLBI NIH HHS/United States
- R37CA54281/CA/NCI NIH HHS/United States
- N01 HC048050/HL/NHLBI NIH HHS/United States
- U01 CA098758/CA/NCI NIH HHS/United States
- U01 HG004798/HG/NHGRI NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- N01 HC075150/HL/NHLBI NIH HHS/United States
- N01 HC065226/HL/NHLBI NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- N01 HC045133/HC/NHLBI NIH HHS/United States
- U01 CA136792/CA/NCI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- N01 HC035129/HC/NHLBI NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- P01CA33619/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous
